Keros Therapeutics Inc (KROS)

R&D Expense Growth

38.73%

Quarterly · Period ending:

KROS logo

KROS R&D Expense Growth

Latest reported38.73%
KROS Quarterly R&D Growth (QoQ) (0.00% → 38.73%)
High-resolution chart · PNG

KROS r&d expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Keros Therapeutics Inc R&D Expense Growth — Quarterly
Period endingR&D Expense Growth
38.7277%
-10.1329%
-8.233%
-55.1318%
-10.688%
6.7454%
-7.3012%
21.4982%
5.8994%
2.0404%
9.8213%
4.9364%
4.6412%
25.0292%
18.1948%
-9.6302%
28.7808%
-4.014%
26.9822%
48.5726%
-13.1535%
18.8237%
15.2353%
15.5699%
-14.8118%
104.9267%
7.9657%
-14.2984%
-7.6022%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.